Astellas(US:ALPMY) Prnewswire·2025-10-08 23:30Core Insights - Astellas Pharma is presenting new data on IZERVAY (avacincaptad pegol intravitreal solution) for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the American Academy of Ophthalmology Annual Meeting (AAO 2025) [1][3] Group 1: Presentation Details - The presentations will include long-term safety and efficacy results from the GATHER2 open-label extension study, real-world evidence on treatment patterns, and insights on disease progression related to GA [2][3] - Key presentations include: - "Avacincaptad Pegol for GA: 3-year Results from the GATHER2 Open-Label Extension Trial" by A. Khanani on October 17, 2025 [3] - "Treatment Patterns and Safety of Avacincaptad Pegol in Real-World Patients With GA" by D. Borkar on October 17, 2025 [3] - "Structure-Function Link of Ellipsoid Zone Integrity and Low Luminance Deficit in Avacincaptad Pegol-Treated Eyes With Geographic Atrophy" by R. Downes [3] Group 2: Product Information - IZERVAY is approved for the treatment of GA in the United States and Japan, while remaining investigational in other regions [3] - The drug is a prescription eye injection used to treat GA, which is a severe form of dry AMD leading to significant vision loss [8] Group 3: Clinical Trial Insights - The GATHER clinical trials (GATHER1 and GATHER2) demonstrated that IZERVAY met its primary endpoint, evaluating safety and efficacy through randomized, double-masked, sham-controlled studies [9] - GATHER1 enrolled 286 participants, while GATHER2 had 448 participants, with safety evaluated in over 700 patients across both trials [9]